To further understand the mechanism underlying the acquisition of drug resistance through persistence, we sought to decipher the transcriptional adaptation of OAC cells to the anti-tumour activity of HER2-targeting agents in order to identify novel actionable therapeutic opportunities. The gene discussed is ERBB2; the disease is neoplasm.